NDAC open hearing
This article was originally published in The Tan Sheet
Executive Summary
Those wishing to speak during public comment section of Sept. 19-20 NDAC meeting on acetaminophen, NSAID, aspirin safety must submit their final statements to FDA by Sept. 4, along with full disclosure on potential conflicts of interest. Submissions should be labeled either "Open APAP," "Open NSAIDs" or "Open ASA," FDA advises, noting "we think separate submissions" on each type of analgesic "would be desirable, but you can use your own judgement." All statements will be posted on 1FDA's Web site before the meeting, agency adds...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.